Fingerprint
Dive into the research topics of '177Lu-Dotatate plus long-acting octreotide versus high‑dose long-acting octreotide in patients with midgut neuroendocrine tumours (NETTER-1): final overall survival and long-term safety results from an open-label, randomised, controlled, phase 3 trial'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically